NIH #R01CA279749
Integrating patient-reported outcomes and T-cell receptor sequencing to predict immune-related adverse events
Active
- Amount
- $600K–$700K
- Period
- 2024-01-19 → 2028-12-31
- PIs
- 1
Awarded at UNIVERSITY OF TX MD ANDERSON CAN CTR
Full Professor(heuristic)
Cancer Immunotherapy and Biomarkers · Oncology
Compare more Oncology professors.
h-index75
i10-index296
Publications1,067
Citations23,924
Grants
2 total · 1 active
NIH #R21CA137633
Phase I Study of IMC-A12 in Combination with Temsirolimus
- Amount
- $300K–$400K
- Period
- 2009-06-15 → 2011-05-31
- PIs
- 1
Awarded at UNIVERSITY OF TX MD ANDERSON CAN CTR
Active grants are a starting point, not proof of an opening. Confirm recruiting and funding with the professor, current students, and your written offer. Learn how to verify PhD funding →
Recent Public Signals
- New paper: Artificial intelligence-guided analysis of the tumor microenvironment predicts response to pembrolizumab in rare tumors (Journal for ImmunoTherapy of Cancer)2026-06-01
- New preprint: Supplementary Figure S1 from Phase Ib Study of Pembrolizumab in Combination with Intratumoral Injection of <i>Clostridium novyi</i>-NT in Patients with Advanced Solid Tumors2025-09-15
- New NIH award: Integrating patient-reported outcomes and T-cell receptor sequencing to predict immune-related adverse events2024-01-19
Are you this professor?
No account needed — verify once with your ORCID iD to set recruiting status and correct your rank.
Data Freshness
- Publications as of 2026-07-09
- Grants as of 2026-09-03
Data may not be current
Find elsewhere
ORCID: 0000-0002-4803-8513